PHARMANUTRA S.P.A. PHARMANUTRA S.P.A.: PUBLICATION OF THE 2022 CORPORATE EVENTS CALENDAR
Pisa, 14TH January 2022 - PharmaNutra S.p.A.(the "Company") announces the dates for the approval of the financial results of the Company by the Board of Directors and the Shareholders' Meeting:
Date
March 21st, 2022
April 26th, 2022
May 9th, 2022
September 5th, 2022
November 7th, 2022
Event
Board of Directors for the approval of the Financial Statements as of 31st December 2021
Ordinary Shareholders' Meeting for the approval of the Financial Statements as of 31st December 2021
Board of Directors Meeting for the approval of the Interim Management Statements as of 31st March 2022
Board of Directors Meeting for the approval of the Half-Yearly Report as of 30th June 2022
Board of Directors Meeting for the approval of the Interim Management Statements as of 30th September 2022
Any amendments to the above calendar will be notified to the market timely.
PharmaNutra S.p.A.
Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by considerable scientific proof. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 130 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in 50 countries abroad, through 32 partners selected from among the finest pharmaceutical companies. Over the years, PharmaNutra has stood out in the production of iron-based nutritional supplements with the trademark SiderAL®, where it can claim important Sucrosomial Technology® patents. The Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.
PharmaNutra.it
For further information: | |
PharmaNutra S.p.A. | Press Office - Spriano Communication & Partners |
Via Delle Lenze, 216/b - 56122 Pisa | Via Santa Radegonda, 16 - 20121 Milan |
Tel. +39 050 7846500 | Tel. +39 02 83635708 |
investorrelation@pharmanutra.it | |
Internal Press Office | Matteo Russo |
press@calabughi.com | mrusso@sprianocommunication.com |
Cristina Tronconi | |
ctronconi@sprianocommunication.com |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Pharmanutra S.p.A. published this content on 14 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2022 16:31:00 UTC.
